NEWTON, MA and MURRIETA, CA — Thursday, April 23 — Manifold, the AI platform for life sciences, and Intelliseq, a computational genomics company specializing in automated NGS interpretation, today announced a technology partnership to bring end-to-end genomic analysis and variant interpretation directly into Manifold’s secure, governed environment. The partnership enables organizations across healthcare and life sciences to transform raw next-generation sequencing data into structured, clinically actionable reports within a secure, governed platform and thereby eliminating the fragmented toolchains and manual processes that slow genomic workflows today.
While diminishing sequencing costs have enabled the generation of massive genomic datasets, the challenge has shifted to the tertiary analysis layer. This stage—where raw data must be rapidly filtered and annotated—has become a critical bottleneck in the race to transform unprecedented volume into immediately actionable clinical information. Academic medical centers preparing cases for tumor boards, clinical laboratories scaling diagnostic reporting, and biopharma teams conducting biomarker discovery across large cohorts all face the same challenge: a manual, static interpretation process that cannot scale with high-throughput data, creating a critical disconnect between evolving clinical evidence and the data-driven environments where decisions are made.
The Manifold–Intelliseq partnership formally bridges this gap, creating the opportunity for a unified, end-to-end ecosystem that aligns genomic scale with clinical precision. Intelliseq’s iFlow platform is a cloud-based genomic analysis engine powering the GeneSpect Reporter suite of interpretation modules which automates tertiary analysis across oncology, hereditary disorders , pharmacogenomics (PGx), and polygenic risk scoring (PRS). These capabilities are now able to be integrated directly into Manifold’s secure, governed environment, where sequencing data, clinical records, imaging, and real-world data already converge for cohort exploration, harmonization, and agentic AI-powered analytics. Together, the two companies deliver a seamless pipeline from FASTQ to governed, interpretable insight.
“Most raw and unstructured genomic data is invisible and uninterpretable to AI agents without significant preprocessing. The Intelliseq-Manifold integration changes that: sequencing outputs enter the environment and come out structured, annotated, and immediately legible to AI agents.”— Vinay Seth Mohta, CEO of Manifold
“Intelliseq’s mission is to accelerate the implementation of digital tools for interpreting the clinical significance of genetic variation. This partnership with Manifold means our analysis outputs are immediately available alongside clinical, imaging, and real-world data in a secure research environment — exactly where they need to be to drive decisions in the clinic and the lab.” — Klaudia Szklarczyk-Smolana, Co-Founder & CEO of Intelliseq
Based on customer requirements, ****Manifold can call Intelliseq’s iFlow workflows via secure APIs, returning structured variant annotations, AMP/ACMG classifications, FDA therapy matches, and clinical trial associations directly into Manifold’s user interfaces. Reports generated by Intelliseq’s GeneSpect Reporters which cover oncology, hereditary diseases, and other domains will be accessible within the Manifold platform or could be surfaced to downstream systems such as Epic.
Manifold and Intelliseq anticipate making additional modules and integrations available over time. If you’d like to find out more, contact us at [hello@manifold.ai]
Tumor boards at academic health systems face intense pressure to synthesize genomic evidence from multiple databases under tight time constraints. The combined Manifold–Intelliseq offering automates variant classification, therapy matching, and clinical trial searching, delivering structured tumor profiling reports directly into the clinician’s workflow.
Diagnostic labs scaling NGS-based testing gain access to Intelliseq’s fully automated, end-to-end analysis pipelines — from raw FASTQ data to physician-ready actionable reports — deployed within Manifold’s secure, HIPAA-compliant infrastructure. The modular GeneSpect Reporters streamline the interpretation of germline and somatic variants across a wide array of genome-based medicine contexts, while the VariantMINER interactive environment empowers laboratories to visualize genomic landscapes, execute precise variant selection, and perform dynamic reclassifications tailored to specific clinical and regulatory requirements
Biopharma teams conducting biomarker discovery, patient stratification, and translational research across large cohorts require consistent, reproducible tertiary interpretation at scale. The partnership enables cohort-level variant analysis within Manifold’s platform, where genomic outputs are immediately available alongside clinical, imaging, claims, and other multimodal data for AI-powered analytics, feasibility assessment, and evidence generation.
Manifold is the AI platform for life sciences, accelerating life-changing medicines to patients. Our products speed up workflows in areas from target identification and clinical development to market access and precision medicine in the clinic, while maintaining the governance life sciences requires. Global companies and premier research institutions use Manifold to operate faster and more effectively. Backed by leading investors including Reach Capital, TQ Ventures, Calibrate Ventures, SilverArc Capital, and Industry Ventures, Manifold serves tens of thousands of users across hundreds of organizations globally. Learn more at manifold.ai
Intelliseq specializes in computational genomics, developing advanced algorithms, predictive models, and software for efficient analysis of large-scale human genetic data. Founded in 2014, the company’s iFlow platform enables laboratories, biobanks, and clinical programs worldwide to design and implement customizable genome analysis pipelines supporting diagnostics, treatment optimization, and health monitoring. Intelliseq’s GeneSpect suite of Reporters delivers automated, clinically validated interpretation across somatic oncology, hereditary disease, pharmacogenomics, and polygenic risk scoring. Intelliseq has partnerships with DNAnexus, Genomenon, OGT (Sysmex), and DNA ALLY. The company is ISO 13485 certified and compliant with HIPAA, GDPR, and IEEE 2791-2020 (BCO) standards. Learn more at intelliseq.com.
.svg)
Platform walkthrough tailored to your data environment
Current workflow review and fit assessment
Implementation timeline and resource requirements
